These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 618989)

  • 1. Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate.
    Over J; Bouma BN; van Mourik JA; Sixma JJ; Vlooswijk R; Bakker-Woudenberg I
    J Lab Clin Med; 1978 Jan; 91(1):32-46. PubMed ID: 618989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of human factor VIII. III. Transitions between forms of factor VIII present in cryoprecipitate and in cryosupernatant plasma.
    Over J; Bouma BN; Sixma JJ; Bolhuis PA; Vlooswijk RA
    J Lab Clin Med; 1980 Mar; 95(3):323-34. PubMed ID: 7354239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gel filtration patterns of factor VIII coagulant antigen and factor VIII related antigen in normal and von Willebrand's disease.
    Chediak J; Peake I; Bloom A
    Thromb Haemost; 1983 Aug; 50(2):509-12. PubMed ID: 6415844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease.
    Meyer D; Obert B; Pietu G; Lavergne JM; Zimmerman TS
    J Lab Clin Med; 1980 Apr; 95(4):590-602. PubMed ID: 6965697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.
    Over J; Sixma JJ; Bruïne MH; Trieschnigg MC; Vlooswijk RA; Beeser-Visser NH; Bouma BN
    J Clin Invest; 1978 Aug; 62(2):223-34. PubMed ID: 670391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in hemophilia.
    Tann G
    Southeast Asian J Trop Med Public Health; 1979 Jun; 10(2):218-28. PubMed ID: 524146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease.
    Weiss HJ; Pietu G; Rabinowitz R; Girma JP; Rogers J; Meyer D
    J Lab Clin Med; 1983 Mar; 101(3):411-25. PubMed ID: 6186757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homo- and heterogeneous forms of human factor VIII.
    Vukovich TC
    Thromb Haemost; 1982 Aug; 48(1):98-100. PubMed ID: 6814000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of molecular size of factor VIII/von Willebrand factor in von Willbrand's disease.
    Mikami S; Takahashi Y; Nishino M; Okubo Y; Fukui H
    Thromb Haemost; 1981 Jun; 45(3):272-5. PubMed ID: 6792740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII-related activities in therapeutic concentrates.
    Barrowcliffe TW; Kemball-Cook G; Morris G; Holt JC; Furlong RA; Peake IR
    J Lab Clin Med; 1981 Mar; 97(3):429-38. PubMed ID: 6780643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimers of von Willebrand antigen in therapeutic factor VIII concentrates.
    Vukovich TC
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):831-40. PubMed ID: 2436998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociation of factor VIII in the presence of proteolytic inhibitors.
    Sussman II; Weiss HJ
    Thromb Haemost; 1978 Oct; 40(2):316-25. PubMed ID: 310586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.
    Weiss HJ; Rogers J; Brand H
    J Clin Invest; 1973 Nov; 52(11):2697-707. PubMed ID: 4201262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of sugar composition of factor VIII/von Willebrand factor in von Willebrand's disease: analysis by crossed affinoimmunoelectrophoresis using lectin (ricinus communis agglutinin-120).
    Mikami S; Ueda M; Yasui M; Takahashi Y; Nishino M; Fukui H
    Thromb Haemost; 1983 Apr; 49(2):87-90. PubMed ID: 6408753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophoretic heterogeneity of normal factor VIII/Von Willebrand protein, and abnormal electrophoretic mobility in patients with Von Willebrand's disease.
    Sultan Y; Simeon J; Caen JP
    J Lab Clin Med; 1976 Feb; 87(2):185-94. PubMed ID: 1082003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Von Willebrand's syndrome. Studies on a variant factor VIII.
    Hill FG; Chan MC; Hardisty RM
    Haemostasis; 1976; 5(5):276-84. PubMed ID: 797643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabbit antibodies against the procoagulant activity (VIII:C) of human factor VIII. Some theoretical and practical considerations on the human factor VIII molecule using heterologous antibodies.
    Tran TH; Marbet GA; Duckert F
    Thromb Haemost; 1981 Dec; 46(4):699-705. PubMed ID: 6800051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical evaluation of the available methods for the determination of factor VIII von Willebrand.
    Casonato A; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(5):670-84. PubMed ID: 2435633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.